Extension of strategic partnership Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has officially extended its long-standing strategic collaboration with Bristol Myers Squibb (BMS) until 2035. This follows a previous extension in 2021 that had committed the alliance through 2030. The relationship originated in 1998 and has spanned over 25 years, making BMS Syngene’s longest-standing strategic partner.
Expansion of integrated service scope The new agreement extends the duration and broadens the range of integrated services across the entire drug development lifecycle, including:
-
Early stage: Discovery research (chemistry, biology), drug metabolism, and pharmacokinetics.
-
Development stage: Translational sciences, pharmaceutical development, and manufacturing.
-
Clinical support: Execution of clinical trials, data management, and integrated information technology services. The expansion aims to enable a seamless progression from initial research to global commercialization.
The Role of the BBRC Center The cornerstone of this collaboration is the Biocon Bristol Myers Squibb Research and Development Center (BBRC). Currently, this facility houses approximately 700 Syngene scientists operating as an extension of BMS’s global research organization. The BBRC focuses on key therapeutic areas, including cardiovascular disease, fibrosis, immunology, and oncology. Since its inception, the center has played a pivotal role in accelerating the transition of novel compounds from discovery to first-in-human studies, helping to optimize development timelines and overall costs.